BioPharm Brief: RNAi, Obesity, and Diabetes Advances

Jun 09, 10:49 PM
Headliner
Share
Subscribe

This week's BioPharm Brief highlights City Therapeutics' efforts to advance its RNAi pipeline with a new financing round, positive Phase 3 data for survodutide in obesity and MASLD, and Lilly's oral GLP-1 Foundayo outperforming oral semaglutide in a landmark head-to-head type 2 diabetes trial.

Share
Subscribe
Next
The BioPharm Brief: Myeloma, Hemophilia, and KRAS
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Regulatory Shifts, Rare Disease Innovation, and Precision Drug Development Trends
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief